|
Anastrozole
1 mg po qd
____________________________________________________________
Exemestane
25 mg po qd
____________________________________________________________
Letrozole
2.5 mg po qd
REF:
JCO 19:2596,2001
TTP significantly longer for letrozole vs tamoxifen (median, 41 v 26 weeks). Letrozole reduced risk of progression by 30% (hazards ratio, 0.70; 95% CI, 0.60 to 0.82, P=.0001). TTP was significantly longer for letrozole irrespective of dominant site of disease, receptor status, or prior adjuvant antiestrogen therapy. Similarly, TTF was significantly longer for letrozole (median, 40 v 25 weeks). ORR was higher for letrozole (30% v 20%; P = .0006), as was the rate of clinical benefit (49% v 38%; P = .001). Survival data are currently immature. CONCLUSION: Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate. Our results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer.
other refs
Cancer 80:218, 1997
JCO 16:453, 1998
____________________________________________________________
Megestrol
40 mg po qid
(or 80 mg po bid)
____________________________________________________________
Tamoxifen
10 mg po bid
(or 20 mg po qd)
____________________________________________________________
Toremifene Citrate
60 mg po qd
REF: JCO 13:2556, 1995
40 mg po qd
REF: JCO 18(20):3487,2000
____________________________________________________________
|
